Logo image of TMDI

TITAN MEDICAL INC (TMDI) Stock Fundamental Analysis

NASDAQ:TMDI - Nasdaq - CA88830X8199 - Common Stock - Currency: USD

0.14  -0.05 (-26.32%)

After market: 0.1241 -0.02 (-11.36%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TMDI. TMDI was compared to 189 industry peers in the Health Care Equipment & Supplies industry. TMDI has a bad profitability rating. Also its financial health evaluation is rather negative. TMDI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TMDI has reported negative net income.
TMDI had a negative operating cash flow in the past year.
TMDI Yearly Net Income VS EBIT VS OCF VS FCFTMDI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -20M -40M

1.2 Ratios

The profitability ratios for TMDI are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TMDI Yearly ROA, ROE, ROICTMDI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 5K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TMDI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TMDI Yearly Profit, Operating, Gross MarginsTMDI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

TMDI does not have a ROIC to compare to the WACC, probably because it is not profitable.
TMDI has more shares outstanding than it did 1 year ago.
TMDI has a better debt/assets ratio than last year.
TMDI Yearly Shares OutstandingTMDI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
TMDI Yearly Total Debt VS Total AssetsTMDI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -26.47, we must say that TMDI is in the distress zone and has some risk of bankruptcy.
TMDI has a worse Altman-Z score (-26.47) than 89.67% of its industry peers.
TMDI has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
TMDI has a Debt to Equity ratio (0.17) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z -26.47
ROIC/WACCN/A
WACC8.45%
TMDI Yearly LT Debt VS Equity VS FCFTMDI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M -40M

2.3 Liquidity

TMDI has a Current Ratio of 1.41. This is a normal value and indicates that TMDI is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.41, TMDI is not doing good in the industry: 82.63% of the companies in the same industry are doing better.
TMDI has a Quick Ratio of 1.41. This is a normal value and indicates that TMDI is financially healthy and should not expect problems in meeting its short term obligations.
TMDI has a worse Quick ratio (1.41) than 69.01% of its industry peers.
Industry RankSector Rank
Current Ratio 1.41
Quick Ratio 1.41
TMDI Yearly Current Assets VS Current LiabilitesTMDI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.21% over the past year.
The Revenue for TMDI has decreased by -50.23% in the past year. This is quite bad
EPS 1Y (TTM)61.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.64%
Revenue 1Y (TTM)-50.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TMDI Yearly Revenue VS EstimatesTMDI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 5M 10M 15M 20M
TMDI Yearly EPS VS EstimatesTMDI Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TMDI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TMDI Price Earnings VS Forward Price EarningsTMDI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TMDI Per share dataTMDI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TMDI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TITAN MEDICAL INC

NASDAQ:TMDI (3/9/2023, 8:00:01 PM)

After market: 0.1241 -0.02 (-11.36%)

0.14

-0.05 (-26.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)03-22 2023-03-22
Inst Owners0%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.66M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.57
P/FCF N/A
P/OCF N/A
P/B 2.25
P/tB 3.18
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.09
BVpS0.06
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 98.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.41
Quick Ratio 1.41
Altman-Z -26.47
F-Score1
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)630.45%
Cap/Depr(5y)858.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.64%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-50.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-48.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-906.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1006.26%
OCF growth 3YN/A
OCF growth 5YN/A